887 related articles for article (PubMed ID: 30918055)
1. OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs.
Fröhlich C; Sørum V; Thomassen AM; Johnsen PJ; Leiros HS; Samuelsen Ø
mSphere; 2019 Mar; 4(2):. PubMed ID: 30918055
[TBL] [Abstract][Full Text] [Related]
2.
Barnes MD; Winkler ML; Taracila MA; Page MG; Desarbre E; Kreiswirth BN; Shields RK; Nguyen MH; Clancy C; Spellberg B; Papp-Wallace KM; Bonomo RA
mBio; 2017 Oct; 8(5):. PubMed ID: 29089425
[TBL] [Abstract][Full Text] [Related]
3. Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in
Giddins MJ; Macesic N; Annavajhala MK; Stump S; Khan S; McConville TH; Mehta M; Gomez-Simmonds A; Uhlemann AC
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263067
[TBL] [Abstract][Full Text] [Related]
4. Activity of ceftazidime-avibactam against multidrug-resistance Enterobacteriaceae expressing combined mechanisms of resistance.
López-Hernández I; Alonso N; Fernández-Martínez M; Zamorano L; Rivera A; Oliver A; Conejo MC; Martínez-Martínez L; Navarro F; Pascual A
Enferm Infecc Microbiol Clin; 2017 Oct; 35(8):499-504. PubMed ID: 27887765
[TBL] [Abstract][Full Text] [Related]
5.
Stone G; Wise M; Utt E
Microbiol Spectr; 2024 Mar; 12(3):e0147323. PubMed ID: 38329363
[TBL] [Abstract][Full Text] [Related]
6. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.
Zhang P; Shi Q; Hu H; Hong B; Wu X; Du X; Akova M; Yu Y
Clin Microbiol Infect; 2020 Jan; 26(1):124.e1-124.e4. PubMed ID: 31494252
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial Activity of Ceftazidime-Avibactam and Comparators against Pathogens Harboring OXA-48 and AmpC Alone or in Combination with Other β-Lactamases Collected from Phase 3 Clinical Trials and an International Surveillance Program.
Lin LY; Debabov D; Chang W; Stone G; Riccobene T
Antimicrob Agents Chemother; 2022 Mar; 66(3):e0198521. PubMed ID: 35225651
[No Abstract] [Full Text] [Related]
8. Increased Expression and Amplification of
Li X; Zhang J; Yang C; Li J; Wang J; Huang W; Zeng L; Liang X; Long W; Zhang X
Microbiol Spectr; 2022 Aug; 10(4):e0095522. PubMed ID: 35900090
[TBL] [Abstract][Full Text] [Related]
9. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
Marshall S; Hujer AM; Rojas LJ; Papp-Wallace KM; Humphries RM; Spellberg B; Hujer KM; Marshall EK; Rudin SD; Perez F; Wilson BM; Wasserman RB; Chikowski L; Paterson DL; Vila AJ; van Duin D; Kreiswirth BN; Chambers HF; Fowler VG; Jacobs MR; Pulse ME; Weiss WJ; Bonomo RA
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167541
[TBL] [Abstract][Full Text] [Related]
10. Implementation of Chromatic Super CAZ/AVI
Bianco G; Boattini M; Comini S; Leone A; Bondi A; Zaccaria T; Cavallo R; Costa C
Eur J Clin Microbiol Infect Dis; 2022 Sep; 41(9):1165-1171. PubMed ID: 35933457
[TBL] [Abstract][Full Text] [Related]
11. Defining Substrate Specificity in the CTX-M Family: the Role of Asp240 in Ceftazidime Hydrolysis.
Ghiglione B; Rodríguez MM; Curto L; Brunetti F; Dropa M; Bonomo RA; Power P; Gutkind G
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29632016
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of ceftazidime-avibactam in various combinations for the treatment of experimental osteomyelitis due to Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae.
Davido B; Crémieux AC; Vaugier I; Gatin L; Noussair L; Massias L; Laurent F; Saleh-Mghir A
Int J Antimicrob Agents; 2023 Jan; 61(1):106702. PubMed ID: 36476965
[TBL] [Abstract][Full Text] [Related]
13. Acquisition of a Stable and Transferable
Huang J; Zhang S; Zhao Z; Chen M; Cao Y; Li B
Front Cell Infect Microbiol; 2021; 11():658070. PubMed ID: 34354959
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the in vitro activity of ceftazidime/avibactam against a global collection of multidrug-resistant Klebsiella spp. from the INFORM surveillance programme (2015-2017).
Rossolini GM; Stone GG
Int J Antimicrob Agents; 2020 Sep; 56(3):106111. PubMed ID: 32721602
[TBL] [Abstract][Full Text] [Related]
15.
Kazmierczak KM; Bradford PA; Stone GG; de Jonge BLM; Sahm DF
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249690
[No Abstract] [Full Text] [Related]
16. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
Aktaş Z; Kayacan C; Oncul O
Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
[TBL] [Abstract][Full Text] [Related]
17. Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne
Shields RK; Chen L; Cheng S; Chavda KD; Press EG; Snyder A; Pandey R; Doi Y; Kreiswirth BN; Nguyen MH; Clancy CJ
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031201
[TBL] [Abstract][Full Text] [Related]
18. Ceftazidime-Avibactam resistance in clinical isolates of carbapenem-resistant Klebsiella pneumoniae: A phenotypic and genotypic analysis.
Krithika VM; Ganesan V; Rajendran T
Indian J Med Microbiol; 2024; 49():100603. PubMed ID: 38705276
[TBL] [Abstract][Full Text] [Related]
19. Characterization of β-Lactamase Content of Ceftazidime-Resistant Pathogens Recovered during the Pathogen-Directed Phase 3 REPRISE Trial for Ceftazidime-Avibactam: Correlation of Efficacy against β-Lactamase Producers.
Mendes RE; Castanheira M; Woosley LN; Stone GG; Bradford PA; Flamm RK
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30910899
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial susceptibility testing of Enterobacteriaceae: determination of disk content and Kirby-Bauer breakpoint for ceftazidime/avibactam.
Yang X; Wang D; Zhou Q; Nie F; Du H; Pang X; Fan Y; Bai T; Xu Y
BMC Microbiol; 2019 Nov; 19(1):240. PubMed ID: 31675928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]